Elanco and Aratana Therapeutics finalize deal to mergeJuly 18, 2019Elanco Animal Health has acquired Aratana Therapeutics. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. "Aratana's strong position in the specialty market—with its current portfolio and pipeline—complements Elanco's field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands," says Jeff Simmons, president and chief executive officer of Elanco. "This deal furthers Elanco's value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians and pet owners." Aratana produces Galliprant, a canine NSAID for osteoarthritis for which Elanco has had the exclusive rights to develop, manufacture, and commercialize since 2016. Aratana also contributes two additional products to Elanco's portfolio: Entyce, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Further, Aratana's research and development pipeline will contribute to Elanco's efforts to sustain the introduction of novel and innovative companion animal therapeutics. As a result of the acquisition, Elanco says it is forming a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. This specialty sales force will …
SPONSORED CONTENTA new way to offer multi-organ supportNEW Hill's Prescription Diet Multi-Organ offers therapeutic nutrition for pets that may have conflicting nutritional needs. + Learn More
Why heartworm prevention begins in your practiceApril 24, 2019According to the American Heartworm Society (AMS), it is estimated more than one million dogs have heartworm disease. Spread by mosquitoes, heartworms live in the heart and pulmonary arteries of infected dogs and cats. Left untreated, the disease can lead to heart failure, as well as damage to other organs. To mark Heartworm Awareness Month, we asked Claire Walther, DVM, veterinary specialty operations at Zoetis Petcare, for her take on what veterinarians can do to better convey the need for heartworm prevention to pet owners. 1) What is the single biggest misconception among veterinarians regarding heartworm disease? Biologically, it is how missing one dose of a preventative medication can lead to the development of heartworm disease. We say it to our clients daily, but many of us couldn't explain why if a client asked. In my own practice, I struggled with the answer. Here is a 30-second sound bite I've used with my clients to help simplify what is a complex discussion. "Young heartworms are carried by infected mosquitoes, and it only takes one bite to transmit them to your dog.1 Once in your dog, the young heartworms live just underneath the skin for about a month—this …
FDA approves treatment for urinary incontinence in dogsApril 2, 2019PROIN ER, a tablet for the control of urinary incontinence in dogs, has been approved by the U.S. Food and Drug Administration (FDA). The drug treats urethral sphincter hypotonus, which occurs due to a dog's age and weakening muscles in the urethra. PROIN Chewable Tablets have already been approved by the FDA; however, they are to be administered twice a day, whereas PROIN ER is a once-a-day extended-release formulation. The effectiveness of PROIN ER was observed in a clinical study comprising 119 dogs that had been previously diagnosed with urethral sphincter hypotonus and had been taking PROIN Chewable Tablets. The timeline of the clinical study went as follows: • For the first week, the owners documented whether the dog received the PROIN Chewable Tablet doses and noted the number of urinary accidents the dog had; • Dogs were then given PROIN ER for the first 28 days and the owners proceeded to take note of how many accidents occurred in a day; • In the fourth week, the number of urinary accidents was compared to the first week. It was found 75 of the 104 dogs who completed the study had no accidents on either tablet;
ISU to begin canine anticancer immunotherapeutic agent clinical trialsFebruary 28, 2019Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic. Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored. "Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades," said Chad Johannes, DVM, DACVIM (SAIM, oncology). "Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs." Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv and enter AAHSD004874 in the keyword search.
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy treatment in 18 dogs. Those that received the vaccine lived more than twice as long as the historical, matched control group, with median survival times of 956 days compared to 423 days. The expanded clinical trial is designed to collect additional safety data for the vaccine in dogs that have undergone amputation of the affected limb and have already completed chemotherapy. If the treatment is found to be as safe and effective as it appeared in the initial clinical trial, Aratana will be given full licensure, allowing it to make the drug commercially available. Live Listeria Vector (AT-014) is created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells. It is designed to supplement standard osteosarcoma treatment of amputation …
Meet KC Animal Health Corridor Investment Forum 2018's 12 competitorsAugust 27, 2018Twelve emerging animal health companies from three countries vied last week for investment opportunities in a "Shark Tank" format with more than 200 animal health companies and 40 financial funds at the 10th annual KC Animal Health Investment Forum. "The Global Animal Health Investment Forum is the premier stage for emerging companies to showcase innovations and technologies that have the potential to revolutionize the animal health industry," said Kimberly Young, president of the Kansas City Animal Health Corridor. Each company is given 10 minutes to present their ideas in front of seven judges, including executives from Nestlé Purina PetCare, Bayer Animal Health, Ceva U.S. Holdings, and Petsmart, followed by a five-minute Q&A session. Presenting companies are seeking anywhere from $500,000 to $20 million in funding and have revenue projections of $20 million within five to seven years. "The Investment Forum is really unique," said Roy Stein, founder and CEO of BabelBark. "It gave us exposure to a mix of people with different backgrounds that were open minded and ready to listen to the newest technology. During Global Animal Health Week we connected with significant investors, potential partners and clients that provided us with enough traction to secure funding and …
Zoetis Core EQ Innovator equine vaccine fights five core diseasesAugust 24, 2018Zoetis' new Core EQ Innovator equine vaccine contains all five core equine disease antigens—West Nile, Eastern and Western equine encephalomyelitis, tetanus, and rabies—in one vaccine. Core EQ Innovator provides a safe and effective immune response against the five core equine disease antigens as demonstrated in safety and efficacy trials, Zoetis stated, adding that the vaccine has been field tested in more than 1,000 horses with 99.7 percent of horses being reaction free.2,3 "Viral respiratory and neurologic diseases are the leading preventable causes of death in horses," said Jacquelin Boggs, DVM, MS, DACVIM, senior veterinarian, Equine Technical Services at Zoetis. "While annual vaccination against the core equine diseases has long been an established standard of care, Core EQ Innovator will simplify compliance and help provide protection to all horses against these deadly diseases. We trust this vaccine will better equip veterinarians with the tools they need to help protect the health and well-being of horses." All of the disease antigens in Core EQ Innovator are backed by the Zoetis Equine Immunization Support Guarantee, which provides horse owners and veterinarians with vaccination support, including diagnostic testing and treatment, the company stated. Available in a 1-mL dose and safe …
